Rallybio
RLYB
Performance
About Rallybio
Rallybio is a biotechnology company focused on developing therapies for rare diseases, aiming to change outcomes for patients with complement dysregulation and related hematology conditions. Its pipeline includes assets such as C5 inhibitors with potential best-in-class profiles, and the company emphasizes translational science to convert scientific breakthroughs into life-changing treatments for patients living with rare diseases. Based in New Haven, Connecticut, Rallybio highlights a mission to advance unimagined therapies and better patient outcomes beyond headline-generating results.
Recent News
Candid Therapeutics Acquired by UCB for up to $2.2 Billion
STAT+: Pharmalittle: We’re Reading About an Abortion Pill Controversy, Another UCB Deal, and More News
Rallybio to Acquire Avenzo in $215 Million Private‑Placement‑Backed Merger
Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio
Rallybio to Merge with Avenzo Therapeutics to Advance Next-Generation Oncology Therapies